Nordic Nanovector ASA - Registration of share capital increase in the Norwegian Register of Business Enterprises

Oslo, 14 December 2016: Reference is made to the stock exchange announcement regarding the successful completion of the private placement (the "Private Placement") of Nordic Nanovector ASA (the "Company) published on 6 December 2016. The Company has issued 4,374,244 new shares each with a nominal value NOK 0.20. The share capital increase was registered in the Norwegian Register of Business Enterprises on 14 December 2016.

Following registration of the new share capital pertaining to the Private Placement in the Norwegian Register of Business Enterprises, the Company has an issued share capital of NOK 9,794,923.60 divided into 48,974,618 shares, each with a par value of NOK 0.20.

The articles of association of Nordic Nanovector are available on the Company's webpage.

For further details contact:
Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76


This information is subject to the disclose requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.



About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at